 |
市場調查報告書
商品編碼
1373947
全球食道鱗狀細胞癌市場預測（~2030年）Esophageal Squamous Cell Carcinoma Market Research Report Forecast till 2030 |
||||||
價格
研究期間，全球食道鱗狀細胞癌市場規模預計將以 8.16% 的複合年增長率成長。賁門失弛緩症的流行、研發和產品審批的擴大以及社會意識的提高正在推動市場的發展。
區域考慮
2022年北美市場佔最大市場份額。這是因為食道疾病的流行正在增加市場的興趣。此外，主要參與者對更好治療方案的投資增加預計也將推動市場發展。
歐洲市場佔據第二大市場份額，因為吸煙、菸草和酒精消費的上升趨勢推動了人們對食道鱗狀細胞癌先進治療方案的興趣。此外，醫療服務利用率的提高也有望促進市場發展。
預計2023年至2030年亞太市場將快速發展。這是由於食道鱗狀細胞癌發病率增加以及吸煙、飲酒人群較多等因素造成的。
本報告研究和分析了全球食道鱗狀細胞癌市場，提供市場動態、區域和細分市場分析、公司簡介等。
目錄
第一章執行摘要
第二章市場介紹
第三章研究方法
第四章市場動態
- 概述
- 促進者
- 賁門失弛緩症流行
- 增加研究活動和產品批准
- 提高人們的意識
- 抑製劑
- 治療費用高
- 食道癌治療藥物的副作用
- 機會
- 臨床試驗增加
第五章市場因素分析
- 價值鏈分析
- 研發/設計
- 製造業
- 分銷/銷售
- 售後監控
- 波特五力分析模型
- COVID-19 對全球食道鱗狀上皮市場的影響
- 對需求的影響
- 對供應鏈的影響
- 對市場進入者的影響
- 食道鱗狀細胞癌患者總數：依地區
- 食道鱗狀細胞癌患者預測（2018-2024年）
- 治療護理標準 (SOC)
- 手術標準 (SOC)
- 化療治療標準（SOC）
- 放射治療護理標準 (SOC)
- 免疫治療護理標準 (SOC)
- 其他療法的護理標準 (SOC)
第六章全球食道鱗狀細胞癌市場：依診斷及治療分類
- 概述
- 診斷
- 內視鏡檢查
- CT掃描
- 食道造影
- 正子斷層掃描 (PET)
- 其他
- 治療
- 手術
- 化學處理
- 放射治療
- 免疫療法
- 其他
第七章全球食道鱗狀細胞癌市場：依最終用戶分類
- 概述
- 醫院
- 專科中心
- 其他
第八章全球食道鱗狀細胞癌市場：按地區
- 世界
- 北美
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 意大利
- 西班牙
- 歐洲其他地區
- 亞太地區
- 中國
- 印度
- 日本
- 澳大利亞
- 韓國
- 亞太其他地區
- 其他地區
- 中東
- 非洲
- 拉丁美洲
第9章 競爭格局
- 概述
- 競爭標桿
- 全球食道鱗狀細胞癌市場的關鍵成長策略
- 全球食道鱗狀細胞癌市場開發數量的主要參與者
- 主要發展和增長戰略
- 產品上市/產品批准
- 財務矩陣
- 銷售額（2021）
- 研究與開發支出(2021年)
第十章公司簡介
- F. HOFFMANN-LA ROCHE LTD
- ASTRAZENECA
- CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
- SEAGEN INC.
- ELI LILLY AND COMPANY
- GLAXOSMITHKLINE PLC
- NOVARTIS AG
- BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.
- JACOBIO PHARMACEUTICALS GROUP CO., LTD.
第十一章附錄
Product Code: MRFR/HC/10527-CR
Market Overview
The Esophageal Squamous Cell Carcinoma Market is anticipated to register a CAGR) of 8.16% during the review period. The developing expanding commonness of Achalasia expanded research exercises and item endorsements, and rising public mindfulness are driving market development.
The rising commonness of achalasia help market development because achalasia patients have a higher gamble of Esophageal Squamous Cell Carcinoma than everybody. The diary Archives of Throat reports that 9 to 10 individuals for every 100,000 individuals experience achalasia every year.
Besides, as per the Global Organization for Research on Malignant growth, these rates are 15 and multiple times higher, separately, than the gamble of Esophageal Squamous Cell Carcinoma in everyone. Accordingly, expanding pervasiveness of achalasia will straightforwardly influence the market development of worldwide Esophageal Squamous Cell Carcinoma decidedly.
Market Segmentation
The Market segments of Esophageal Squamous Cell Carcinoma, based on diagnosis and treatment, whereas, diagnosis is further segmented into Endoscopy, CT scan, Esophagram, Positron Emission Tomography (PET) and others.
The Esophageal Squamous Cell Carcinoma Market segmentation is based on end user which includes hospitals, specialty centers and others.
Regional Insights
The North America Esophageal Squamous Cell Carcinoma market represented the biggest market share in 2022. This is because of the rising pervasiveness of esophageal disease which is raising the interest for the Esophageal Squamous Cell Carcinoma treatment market. Additionally, the rising speculation by significant vital participants in better treatment options is likewise expected to cultivate North America's market development.
Europe Esophageal Squamous Cell Carcinoma market represents the second-biggest market share because of the rising tendency towards smoke, tobacco, and drink is driving up interest for a high-level treatment choice for Esophageal Squamous Cell Carcinoma. Additionally, rising medical services use is likewise expected to help the development of the market.
The Asia-Pacific Esophageal Squamous Cell Carcinoma market is supposed to develop at a critical offer from 2023 to 2030. This is because of elements, for example, the rising frequency of Esophageal Squamous Cell Carcinoma, and the high populace of tobacco smoking and liquor savoring this area is additionally expected to support the market development. Besides, the Rising actual inertia and unfortunate way of life are additionally expected to support the development of the provincial market. Additionally, China market of Esophageal Squamous Cell Carcinoma is supposed to hold the biggest market offer, and Rest of Asia-Pacific market is normal quickest developing district.
The Rest of the World is sectioned into the Middle East, Africa, and Latin America. The market in the previously mentioned districts is probably going to observe development because of solid epidemiological factors, and further developing medical services offices, expanding mindfulness about sound ways of life.
Major Players
Key Companies in the market of Esophageal Squamous Cell Carcinoma include Hoffmann-La Roche Ltd, AstraZeneca, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Seagen Inc., Eli Lilly and Company, Glaxosmithkline Plc, Novartis AG, Beijing Shenzhou, Cell Biotechnology Group Co., Ltd., and Jacobio Pharmaceuticals Group Co., Ltd.
TABLE OF CONTENTS
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
- 1.1 OVERVIEW
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
- 2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
- 3.1 DATA MINING
- 3.2 SECONDARY RESEARCH
- 3.3 PRIMARY RESEARCH
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
- 3.5 FORECASTING TECHNIQUES
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
- 3.7 DATA TRIANGULATION
- 3.8 VALIDATION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF ACHALASIA
- 4.2.2 INCREASED RESEARCH ACTIVITIES AND PRODUCT APPROVALS
- 4.2.3 RISING PUBLIC AWARENESS
- 4.3 RESTRAINTS
- 4.3.1 HIGH COST OF TREATMENT
- 4.3.2 SIDE EFFECTS OF ESOPHAGEAL CANCER DRUGS
- 4.4 OPPORTUNITIES
- 4.4.1 RISE IN CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D & DESIGNING
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
- 5.3 IMPACT OF COVID-19 ON THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- 5.3.1 IMPACT ON DEMAND
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON MARKET PLAYERS)
- 5.4 TOTAL NUMBER OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS, BY REGION
- 5.5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENT FORECAST, (2018-2024)
- 5.6 STANDARD OF CARE (SOC) FOR THE TREATMENT
- 5.6.1 STANDARD OF CARE (SOC) FOR SURGERY:
- 5.6.2 STANDARD OF CARE (SOC) FOR CHEMOTHERAPY:
- 5.6.3 STANDARD OF CARE (SOC) FOR RADIOTHERAPY:
- 5.6.4 STANDARD OF CARE (SOC) FOR THE IMMUNOTHERAPY:
- 5.6.5 STANDARD OF CARE (SOC) FOR OTHER TREATMENTS
6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY DIAGNOSIS & TREATMENT
- 6.1 OVERVIEW
- 6.2 DIAGNOSIS
- 6.2.1 ENDOSCOPY
- 6.2.2 CT SCAN
- 6.2.3 ESOPHAGRAM
- 6.2.4 POSITRON EMISSION TOMOGRAPHY (PET)
- 6.2.5 OTHERS
- 6.3 TREATMENT
- 6.3.1 SURGERY
- 6.3.2 CHEMOTHERAPY
- 6.3.3 RADIOTHERAPY
- 6.3.4 IMMUNOTHERAPY
- 6.3.5 OTHERS
7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY END USER
- 7.1 OVERVIEW
- 7.1.1 HOSPITALS
- 7.1.2 SPECIALTY CENTERS
- 7.1.3 OTHERS
8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION
- 8.1 GLOBAL
- 8.2 NORTH AMERICA
- 8.2.1 US
- 8.2.2 CANADA
- 8.3 EUROPE
- 8.3.1 GERMANY
- 8.3.2 UK
- 8.3.3 FRANCE
- 8.3.4 ITALY
- 8.3.5 SPAIN
- 8.3.6 REST OF EUROPE
- 8.4 ASIA-PACIFIC
- 8.4.1 CHINA
- 8.4.2 INDIA
- 8.4.3 JAPAN
- 8.4.4 AUSTRALIA
- 8.4.5 SOUTH KOREA
- 8.4.6 REST OF ASIA-PACIFIC
- 8.5 REST OF THE WORLD
- 8.5.1 MIDDLE EAST
- 8.5.2 AFRICA
- 8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
- 9.1 OVERVIEW
- 9.2 COMPETITIVE BENCHMARKING
- 9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 9.5.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
- 9.6 FINANCIAL MATRIX
- 9.6.1 SALES (USD MILLION), 2021
- 9.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILES
- 10.1 F. HOFFMANN-LA ROCHE LTD
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
- 10.2 ASTRAZENECA
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
- 10.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
- 10.3.1 COMPANY OVERVIEWS
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
- 10.4 SEAGEN INC.
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGIES
- 10.5 ELI LILLY AND COMPANY
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 SWOT ANALYSIS
- 10.5.6 KEY STRATEGIES
- 10.6 GLAXOSMITHKLINE PLC
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 SWOT ANALYSIS
- 10.6.6 KEY STRATEGIES
- 10.7 NOVARTIS AG
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT ANALYSIS
- 10.7.6 KEY STRATEGIES
- 10.8 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 KEY STRATEGIES
- 10.9 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 KEY STRATEGIES
11 APPENDIX
- 11.1 REFERENCES
- 11.2 RELATED REPORTS
LIST OF TABLES
- TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
- TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
- TABLE 3 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 4 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CT SCAN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ESOPHAGRAM, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018-2030 (USD MILLION)
- TABLE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 19 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 20 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 22 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION, 2018-2030 (USD MILLION)
- TABLE 23 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 24 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 25 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 26 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 27 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 28 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 29 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 30 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 31 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 32 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 33 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 34 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 35 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 36 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 37 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 38 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 39 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 40 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 41 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 42 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 43 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 44 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 45 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 46 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 47 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 48 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 49 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 50 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 51 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 52 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 53 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 54 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 55 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 56 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 57 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 58 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 59 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 60 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 61 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 62 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 63 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 64 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 65 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 66 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 67 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030
- TABLE 68 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 69 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 70 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 71 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 72 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 73 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 74 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 75 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 76 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 77 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 78 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 79 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 80 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 81 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 82 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 83 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 84 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 85 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 86 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 87 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 88 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 89 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 90 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 91 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 92 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 93 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 94 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 95 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 96 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 97 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 98 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 99 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 100 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 101 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 102 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 103 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 104 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 105 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 106 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 107 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 108 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 109 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 110 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 111 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2030 (USD MILLION)
- TABLE 112 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 113 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018-2030 (USD MILLION)
- TABLE 114 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018-2030 (USD MILLION)
- TABLE 115 MAJOR PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- TABLE 116 MOST ACTIVE PLAYER IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- TABLE 117 PRODUCT LAUNCHES/PRODUCT APPROVALS
- TABLE 118 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
- TABLE 119 ASTRAZENECA: PRODUCTS OFFERED
- TABLE 120 ASTRAZENECA: KEY DEVELOPMENTS
- TABLE 121 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
- TABLE 122 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: KEY DEVELOPMENTS
- TABLE 123 SEAGEN INC: PRODUCTS OFFERED
- TABLE 124 SEAGEN INC.: KEY DEVELOPMENTS
- TABLE 125 ELI LILLY AND COMPANY: PRODUCTS OFFERED
- TABLE 126 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
- TABLE 127 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
- TABLE 128 NOVARTIS AG: PRODUCTS OFFERED
- TABLE 129 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.: PRODUCTS OFFERED
- TABLE 130 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: PRODUCTS OFFERED
LIST OF FIGURES
- FIGURE 1 MARKET SYNOPSIS
- FIGURE 2 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
- FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- FIGURE 5 DRIVER IMPACT ANALYSIS
- FIGURE 6 RESTRAINT IMPACT ANALYSIS
- FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- FIGURE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET; GENDER SEGMENT ATTRACTIVENESS, (USD MILLION)
- FIGURE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2021 & 2030 (USD MILLION)
- FIGURE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS, 2021 & 2030 (USD MILLION)
- FIGURE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)
- FIGURE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET; END USER SEGMENT ATTRACTIVENESS, (USD MILLION)
- FIGURE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2021 & 2030 (USD MILLION)
- FIGURE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY REGION, 2021 (% SHARE)
- FIGURE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY REGION, 2021 (USD MILLION)
- FIGURE 17 NORTH AMERICA MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
- FIGURE 18 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)
- FIGURE 19 EUROPE MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
- FIGURE 20 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)
- FIGURE 21 ASIA-PACIFIC: MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
- FIGURE 22 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)
- FIGURE 23 REST OF THE WORLD: MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)
- FIGURE 24 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE (%), BY COUNTRY, 2021
- FIGURE 25 BENCHMARKING OF MAJOR COMPETITORS
- FIGURE 26 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET
- FIGURE 27 SALES, 2021
- FIGURE 28 RESEARCH & DEVELOPMENT EXPENDITURE, 2021
- FIGURE 29 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
- FIGURE 30 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS
- FIGURE 31 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
- FIGURE 32 ASTRAZENECA: SWOT ANALYSIS
- FIGURE 33 SEAGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
- FIGURE 34 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
- FIGURE 35 ELI LILLY AND COMPANY: SWOT ANALYSIS
- FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
- FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
- FIGURE 38 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
- FIGURE 39 NOVARTIS AG: SWOT ANALYSIS
- FIGURE 40 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: FINANCIAL OVERVIEW
